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Background/Aims: Many parasites induce changes in the 
lipid profiles of the host. Cholesterol increases the virulence 
of Entamoeba histolytica in animal models and in vitro 
culture. This study aimed to determine, in patients with 
an amebic liver abscess, the correlation between choles-
terol and other features, such as the size and number of 
abscesses, standard hematological and serum chemistry 
profiles, liver tests, and duration of hospital stay. Methods: A 
total of 108 patients with an amebic liver abscess and 140 
clinically healthy volunteers were investigated. Cholesterol 
and triglycerides were measured in the sera. The data from 
medical observations and laboratory tests were obtained 
from the clinical records. Results: A total of 93% of patients 
with an amebic liver abscess showed hypocholesterolemia 
not related to any of the studied parameters. Liver func-
tion tests correlated with the size of the abscess. The most 
severe cases of amebic liver disease or death were found 
in patients whose cholesterol levels continued to decrease 
despite receiving antiamebic treatment and hospital care. 
Conclusions: Our results show that the hypocholesterolemia 
observed in patients with an amebic liver abscess is not re-
lated to any of the clinical and laboratory features analyzed. 
This is the first study relating hypocholesterolemia to severity 
of hepatic amebiasis. (Gut Liver 2014;8:415-420)
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INTRODUCTION
The disease caused by Entamoeba histolytica constitutes 
the third cause of morbidity by parasite infection giving rise 
mortality with 70,000 deaths yearly worldwide, surpassed only 
by malaria and schistosomiasis. The incidence of amebiasis is 
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higher in developing countries. Invasive intestinal amebiasis 
presents acute ulcerative colitis, toxic megacolon, ameboma, 
or amebic appendicitis. When trophozoites spreading via the 
bloodstream, invade other organs, causes extraintestinal am-
ebiasis; mainly amebic liver abscesses (ALA).1 Less than 10% of 
patients with invasive extraintestinal amebiasis release amoebas 
in stool.2 There are cases of ALA in persons of all ages, but it is 
more common observed in men than women.3,4
Bansal et al.5 reported that most of the parasites induce sig-
nificant changes in lipid profiles in patients having active infec-
tions. In experimental models, animals cholesterol-fed are more 
susceptible to develop an ALA than animals under routine feed-
ing.6,7 The ameboma rarely occurs in guinea pigs, but if they are 
cholesterol-fed, they develop ameboma when infected intrace-
cally with E. histolytica trophozoites.8
In vitro, E. histolytica became avirulent after more than 2 
years of maintenance in axenic culture, but regains its virulence 
if cholesterol or phosphatidylcholine-cholesterol (PC-Chol) li-
posomes are added to culture.9-14 Cholesterol-rich domain (lipid 
rafts) on the cell surface have been shown to control virulence 
in a variety of parasites, including E. histolytica.15,16
The aim of this study was to determine, in patients with ALA, 
the correlation between cholesterol and other features as size 
and number of abscesses, standard hematologic and serum 
chemistry profile, liver tests and hospital stay.
MATERIALS AND METHODS
1. Patients
This study included 108 patients with diagnosis of ALA ad-
mitted to “Jose Eleuterio González” University Hospital, Uni-
versidad Autónoma de Nuevo León. Monterrey, Nuevo León, 
Mexico from 2002 to 2011. Serum samples from 140 clinically 
healthy volunteers were included. Levels of cholesterol and tri-
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glycerides were established from the control group, representing 
healthy population inhabiting an amebiasis endemic area.
2. Experimental design
The ALA was confirmed by ultrasound image or computed 
tomography. The sera of all patients included had positive two 
tests to diagnose invasive amebiasis; indirect hemagglutination 
assay (IHA Cellognost Amoebiasis; Behring Diagnostics GmbH, 
Marburg, Germany) and the western blot test patented by us.17-21
The standard treatment of liver abscess was the use of appro-
priate antibiotics and supportive care. Based on clinical unre-
sponsive to therapy, some patients underwent needle aspiration 
of abscess to promote recovery. Sonographic examination of 
the upper abdomen was conducted in the patients. After a lesion 
was located and identified within the liver, percutaneous drain-
age was performed under ultrasound guidance and asepsis. To 
evacuate the abscess the fluid was aspirated as much as possible 
using Chiba needles, 18 to 22 gauge, and 15 to 20 cm long. The 
needle was selected according to the abscess cavity volume. 
During the aspiration, the needle was under screen control. The 
drained pus was examined microscopically for the presence of 
trophozoites and polymorphonuclear leukocytes. The aspirated 
pus underwent microbiologic examination to discard bacterial 
coinfection. E. histolytica culture was not made. Stool samples 
were not examined because only less than 10% of patients with 
liver abscess release amebas in stool.2
Cholesterol and triglycerides were determined in sera by 
enzymatic-spectrophotometric test (Biosystems S.A., Barcelona, 
Spain). The inpatients medical records were reviewed to obtain 
the volume of the amebic abscesses, localization and numbers 
of the abscesses. From records also were acquired the number 
of punctures, the stay at the hospital, hematology and standard 
liver function test results including alanine transaminase (ALT), 
aspartate transaminase (AST), alkaline phosphatase (ALP), lac-
tate dehydrogenase (LDH), total bilirubin (TBIL), direct bilirubin 
(conjugated bilirubin), gamma glutamyl transpeptidase (GGT).
The area of the abscess was measured directly during ultra-
sound examination. First, it was measured the x-axis and then 
the plane perpendicular to determine the y-axis. When it was 
possible, the plane z was measured. In case of multiple abscess-
es, it was taken into account the largest one. The area of the 
abscesses was calculated by multiplying the measures of x-axis 
by y-axis. 
Healthy volunteers were living at Monterrey, an area that 
is endemic for amebiasis. The sera belonging to healthy group 
had negative the western blot and the commercial IHA test to 
diagnose invasive amebiasis. They had not detected parasites in 
feces, and they never had invasive amebiasis, nor recall an epi-
sode of bloody diarrhea within the previous year. 
This research is part of a broader research protocol, and the 
consent forms were approved by the Ethics Committee of the 
Hospital and by the Ethics Committee of the Faculty of Biologi-
cal Sciences.
3. Statistical analysis
The data were analyzed using the Statistical Package SPSS 
version 19.0 (SPSS Inc., Chicago, IL, USA) employing correla-
tion coefficients of Pearson or Spearman. Nominal variable was 
analyzed by contingency table. Results with p-values <0.05 
were considered as statistically significant.
RESULTS
1. Demographic features
The demographic features of patients with ALA were 20 
women with an average age of 53±14 years and 88 men with 
an average age of 35±16 years. The healthy volunteers were 60 
women aged 30±18 years and 80 men aged 32±20 years. Dif-
ferences between the groups were no significant (p>0.05).
2. Cholesterol values of ALA patients
Dispersion of cholesterol values of ALA patients shows a ten-
dency of low values (Fig. 1). Hypocholesterolemia was found in 
94 ALA patients (87%); 51 (47.2%) presented levels of <100 mg/
dL. The minimum level found was 15 mg/dL. Fourteen samples 
had normal values and only one patient had hypercholesterol-
emia. The sera from healthy women showed a mean of 148±32 
mg/dL and healthy men showed a mean of 170±38 mg/dL. 
3. Size, number, and localization of the amebic abscesses
The size of the amebic abscesses was variable. Some of them 
had 3×2 cm, while other abscesses measured 17×13 cm or 
11×13.6 cm. The mean of the abscess area was 73 cm2 and the 
median was 51 cm2. The measures of abscesses were taken from 
records; the reports of 60% abscesses had measures in the x-, 
y-, and z-axis, and 40% only in x- and y-axis; therefore, solely 
Fig. 1. Distribution of cholesterol levels in amebic liver abscess (ALA) 
patients. The serum cholesterol level was determined in 108 patients 
using the enzymatic-spectrophotometric test from ByosSystems. Nor-
mal level: 140 to 200 mg/dL.
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the area of the abscesses were calculated instead volume. Sev-
enty percent ALA patients had a single abscess, and 30% had 
multiple abscesses. Ninety-four patients showed abscesses in the 
right lobe, nine had abscesses in both lobes, and four in the left 
lobe (Fig. 2). The size or localization of the amebic abscess did 
not present correlation with hypocholesterolemia, neither the 
numbers of the abscess (p>0.05). Thirteen patients underwent 
to needle aspiration, and four patients needed more than three 
functions (Table 1).
4. Hypocholesterolemia and days of hospital stay
Patients with ALA stay at the hospital an average of 10 days, 
with a minimum of 4 days and maximum 28 days. Hypocholes-
terolemia does not correlate with the hospital stay required by 
the patients (p>0.05). However, 84% patients whose cholesterol 
levels continue to decrease required more than 10 days at the 
hospital (Table 1).
5. Characteristics of patients with cholesterol values de-
creasing despite antiamebic treatment
The most common complaints among patients were abdomi-
nal pain, asthenia, and anorexia. Patients with cholesterol levels 
descending, despite receiving antiamebic treatment and hospital 
care, presented the most severe cases of amebiasis with rupture 
of the abscess or even death. These patients needed multiple 
percutaneous drainages and required 21 to 28 days at the hos-
pital. All required multiple punctures despite antiamebic treat-
ment. Three patients had multiple abscesses and the other three 
patients had a single abscess. The range of fluid drained in the 
punctures was 15 to 900 mL on each puncture. A patient died 
due that the abscess invaded the lung and had pleural effusion 
and liver dysfunction. His cholesterol level was 109 IU/L when 
he entered the hospital and the cholesterol levels continued 
decreasing until it reached a minimum level of 42 IU/L after 9 
days at hospital.
6. Clinical laboratory and liver function tests from ALA pa-
tients
The median of triglycerides obtained from ALA patients lev-
els were 89 mg/dL. High levels of triglycerides were observed 
in two ALA patients (253 and 505 mg/dL). The rest of these 
patients had normal levels. Healthy persons presented a median 
of 70 mg/dL. The differences in triglyceride levels among both 
groups were not significant (p>0.05) (Table 2).
All the ALA patients presented high white blood cell count 
15,903±3,786 mm3 (normal, 4,000 to 7,000 mm3); high neutro-
phil count 82%±15% (normal, 35% to 70%) and low lympho-
cytes 13%±6% (normal, 20% to 50%). No correlation was found 
among hypocholesterolemia, and these features (p>0.05). The 
ALA patients showed results of other standard clinical labora-
tory tests within normal limits. Forty-three (49%) of the ALA 
patients had high AST, 40 (43%) ALT, 42 (45%) LDH, but no 
correlation was found with hypocholesterolemia neither the size 
of the abscess (p>0.05). Ninety-one (85%) of the ALA patients 
Table 1. Correlation between Cholesterol and Some Variable Factors 
in Patients with an Amebic Liver Abscess
Variable factor
Cholesterol
Correlation coefficient p-value
Age 0.326 >0.05
Gender, male/female 0.147 >0.05
Size of the abscess -0.034 >0.05
Days of hospital stay -0.073 >0.05
No. of the amebic abscesses -0.236 >0.05
Localization of the amebic abscesses 0.173 >0.05
Pearson correlation was used for normally distributed variables, and 
for nonnormally distributed parameters, Spearman correlation coeffi-
cients were used. A contingency table was used for nominal vari-
ables. p<0.05 was considered to be statistically significant.
Fig. 2. Localization and area of amebic liver abscess in patients with invasive amebiasis.
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had low albumin to globulin (A/G) ratio, instead 74 (69%) had 
total and direct bilirubin elevated, 81 (76%) presented GGT 
elevated, 80 (75%) ALP. These features do not correlate with 
hypocholesterolemia (p>0.05) (Table 2); by contrast, these data 
are correlated to the size of the abscess (p<0.05). The larger the 
abscess is, more altered are the above test (Table 3).
DISCUSSION
The ALA patients studied in our series presented hypocho-
lesterolemia in 93% of cases. Other authors reported abnormal 
cephalin-cholesterol flocculation test in patients with ALA and 
patients with intestinal amebiasis.22,23 Bansal et al.24 found sig-
nificantly lower levels of lipid profile in ALA patients and cyst 
passers of E. histolytica or E. dispar, compared with healthy 
controls.
The laboratory features of ALA patients recorded in this study 
agreed with previous reports.1,3,22 No correlation was found 
among hypocholesterolemia and data of laboratory standard 
tests or the liver function tests. Low A/G ratio and high total 
bilirubin, direct bilirubin, GGT, and ALP had a correlation with 
the size of the abscess as has been reported previously,25 but 
not with hypocholesterolemia. Liver function tests in some ALA 
patients studied by us, suggests cholestasis, as has been reported 
previously.26,27
We did not find correlation between the hypocholesterolemia 
and the size of the abscess, nor their location or the numbers of 
the abscess. Patients with small abscesses show hypocholester-
olemia as well as patients with big abscesses. We detected no 
correlation between hypocholesterolemia, and the hospital stay 
required by the patients. However, patients whose cholesterol 
levels continue to decrease after hospital care, and antiamebic 
treatment initiation, required multiple punctures and more days 
of hospitalization. Some of them presented the most serious 
cases of amebiasis with rupture of the abscess and pleural effu-
Table 2. Correlation between Hypocholesterolemia and Standard Hematology Profile in Patients with an Amebic Liver Abscess
Test Normal range ALA patient (mean±SD) Correlation coefficient p-value
Hemoglobin, g/dL 12–16 12±4 0.239 >0.05
Hematocrit, % 37–47 33±6 0.308 >0.05
Leukocytes, /mm3 4,800–10,800 15,903±3,786 0.038 >0.05
Lymphocytes, % 19–48 13±6 0.095 >0.05
PMN, % 40–74 82±15 0.209 >0.05
Triglycerides, mg/dL <150 101±88 0.256 >0.05
Total bilirubin, mg/dL 0.1–1.0 2.4±2 0.158 >0.05
Direct bilirubin, mg/dL 0.0–0.4 1.5±2 0.009 >0.05
AST, IU/L 6–42 97.7±144 -0.057 >0.05
ALT, IU/L 10–56 67.5±70 -0.186 >0.05
LDH, IU/L 91–245 302.4±186 -0.034 >0.05
GGT, IU/L 7–64 145.5±123 0.010 >0.05
ALP, IU/L 30–121 207.8±109 0.083 >0.05
Total protein, g/dL 6.0–8.3 6.7±1 0.134 >0.05
A/G ratio 3.2–5.5 2.6±1 0.227 >0.05
Pearson correlation was used for normally distributed variables, and Spearman correlation coefficients were used for nonnormally distributed pa-
rameters. p<0.05 was considered to be statistically significant.
ALA, amebic liver abscess; PMN, polymorphonuclear; direct bilirubin, conjugated bilirubin; AST, aspartate aminotransaminase; ALT, alanine ami-
notransaminase; LDH, lactate dehydrogenase; GGT, gamma glutamyltranspeptidase; ALP, alkaline phosphatase; A/G, albumin/globulin.
Table 3. Correlation between Liver Function Tests and Abscess Size 
in Patients with an Amebic Liver Abscess
Test Correlation coefficient p-value
Triglycerides, mg/dL 0.229 >0.05
Total bilirubin, mg/dL 0.096 >0.05
Direct bilirubin, mg/dL 0.327 <0.05
AST, IU/L 0.282 >0.05
ALT, IU/L 0.150 >0.05
LDH, IU/L 0.021 >0.05
GGT, IU/L 0.388 <0.05
ALP, IU/L 0.419 <0.05
Total protein, g/dL -0.213 >0.05
A/G ratio -0.369 <0.05
Pearson correlation was used for normally distributed variables, and 
Spearman correlation coefficients were used for nonnormally distrib-
uted parameters. p<0.05 was considered to be statistically significant.
Direct bilirubin, conjugated bilirubin; AST, aspartate aminotransami-
nase; ALT, alanine aminotransaminase; LDH, lactate dehydrogenase; 
GGT, gamma glutamyltranspeptidase; ALP, alkaline phosphatase; A/G, 
albumin/globulin.
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sion, or even death. In the contrary, cholesterol levels were ris-
ing in patients with initial low cholesterol values that responded 
to treatment. Gujral et al.28 found triglycerides, cholesterol in-
creased in liver of hamsters infected with E. histolytica tropho-
zoites while these animals showed hyperlipidemia and hypo-
cholesterolemia in serum. Our data from ALA patients does not 
agree with the above animal model, because we have detected 
normal values of triglycerides in sera; only two patients pre-
sented high values. Perhaps the difference in the data obtained 
by our group could be explained by differences in lipid process-
ing between hamsters and humans. The hypocholesterolemia 
reported in hamsters models, tended to normalize in relation 
to the metronidazole treatment period.28 It still remains to be 
determined the period required by ALA patients to recover the 
normal levels of cholesterol after antiamebic treatment.
The role of lipids is essential to maintaining the structure of 
membranes, participate in protein folding, in transport, signal 
transduction pathways, growth, differentiation, and the mainte-
nance of cellular physiology.29 E. histolytica lack mitochondria. 
However, they survive and multiply by scavenging nutrients 
from the host. It has been reported that E. histolytica is unable 
to synthesize the majority of their own lipids and cholesterol de 
novo and scrounge them on the host or the growth medium.30 
Apparently, E. histolytica take exogenous phospholipids to 
undergo fatty acid remodeling by deacylation/reacylation re-
actions, bypassing the synthesis of entirely new phospholipid 
molecules.30 Phospholipases are considered key enzymes of the 
deacylation/reacylation of lipid molecules, and E. histolytica 
are rich in phospholipases and lysophospholipase important for 
cytolysis of target cells.31 E. histolytica are capable of elongat-
ing/desaturating long-chain fatty acids, and assembling novel 
glycophospholipid molecules.32,33 Lipid molecules stimulate the 
kinases expression. It has been proposed that trans membrane 
kinases may be important molecules involved in cellular pro-
liferation, virulence and erythrophagocytosis of E. histolytica.34 
Important E. histolytica virulence factors are composed by lipids 
as the surface antigens Gal/GalNAc lectin and the lipophospho-
glycanlike.35-38 Antilipophosphoglycan antibodies reduce the 
ability of the parasite to invade host mammalian cells, and pre-
vented ALAs.39 Recently, Seifert et al.40 reported that analogs of 
alkylphosphocholines possess antiamebic activity.
The above information indicates the importance of lipids in 
vital processes of amebas, so probably they consume cholesterol 
from the host to obtain and metabolize lipids. Most of the cho-
lesterol moves through the enterohepatic circulation as E. his-
tolytica do, therefore, we propose that protozoa mainly invade 
organs where cholesterol may be available in larger quantities 
like liver and intestine. Further studies are needed for better 
understanding how E. histolytica is involved in hypocholester-
olemia.
This is the first report that correlates hypocholesterolemia 
with the severity of hepatic amebiasis. We propose that it is 
important to survey cholesterol levels to predict the outcome of 
patients with invasive amebiasis.
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